Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Low response to ovarian stimulation in women with BRCA mutations
- Women with BRCA mutations have poorer cycle outcomes
- Lower AMH in women with BRCA mutations
- No change in AMH with BRCA mutations?
- BRCA mutations & age at natural menopause
- Genes associated with early-age menopause
- BRCA mutations & fertility
- Difficulties in studying fertility in women with BRCA mutations
- BRCA-mutation related ovarian dysfunction
- Role of BRCA
- DNA repair declines with age in oocytes/sperm
- Ovarian aging is accelerated with BRCA mutations
- Overall aging is accelerated with BRCA mutations
- Consequences of loss of BRCA function
- Are women with BRCA mutations more likely to lose ovarian reserve after chemotherapy?
- Study design
- Calculation of ovarian recovery
- Study population characteristics & raw AMH
- Lower age-adjusted baseline AMH levels
- Impact of BRCA mutations on chemotherapy-induced ovarian insufficiency
- Lower post-chemo recovery of AMH in BRCA mutation carriers
- Post-chemo ovarian recovery %
- Single cell silencing of BRCA1
- Ovarian cortex freezing
- Ovarian transplantation approaches
- Other ovarian transplantation approaches
- Heterotopic transplant: pros & cons
- Meta-analysis of livebirths after ovarian transplantation with frozen banked tissue
- Frozen-thawed ovarian tissue transplant outcomes
- Extra-cellular matrix scaffold to improve ovarian transplant
- Robot-assisted ovarian transplant
- Ovarian transplantation techniques
- Outcomes of robotic ovarian transplant techniques
- Robotic ovarian transplants resulted in live births
- Current outcomes
- Robotic ovarian transplant outcomes: summary data (5/19/20)
- Major weaknesses of GnRHa RCTs
- A quality–based assessment of GnRHa RCTs
- 6/7 RCTs did not show FP benefit with GnRHa
- GnRHa will not & cannot preserve fertility
- What is the harm in giving GnRHa?
- Poor obstetrical outcomes following GnRHa treatment
- S1P reduces chemotherapy-induced primordial follicle death
- Enhancing DNA repair to protect oocytes
- Conclusions
- Thank you
Topics Covered
- Reproductive Biology
- Fertility
- Pregnancy and Cancer
- BRCA Mutations
- Robotic Ovarian Transplant
Links
Series:
- The Female Reproductive System: from Basic Science to Fertility Treatments
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Oktay, K.H. (2021, August 29). Preservation of fertility in cancer patients: BRCA mutations, ovarian tissue cryopreservation and transplantation, and pharmacological treatments in fertility preservation [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 20, 2024, from https://doi.org/10.69645/QTWQ1550.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Kutluk H. Oktay has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Preservation of fertility in cancer patients: BRCA mutations, ovarian tissue cryopreservation and transplantation, and pharmacological treatments in fertility preservation
Published on August 29, 2021
41 min
Other Talks in the Series: The Female Reproductive System: from Basic Science to Fertility Treatments
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome back.
In part 1, we talked about ovarian reserve and chemotherapy,
how we make decisions for fertility preservation,
and how we approach fertility preservation in women with breast cancer.
In part 2, I'll be talking to you about how BRCA mutations affect ovarian reserve and reproduction.
0:22
An interesting observation we made while we were developing
the letrozole protocol and tamoxifen protocols in women with breast cancer,
was that those with BRCA mutations tended to have fewer oocytes on average.
If you had a BRCA1 mutation you would have a mean number of 7.4 oocytes,
compared to a BRCA mutation-negative person with 11.3.
Moreover, you can see on the bar graph that women with BRCA mutations
had something like 30 to 40 times higher risk of having a low response to ovarian stimulation
(especially the BRCA1 type), compared to those untested and negative.
1:06
In a more recent study, we confirmed these findings,
where we compared the ovarian stimulation response
between women who were BRCA-negative or untested, and those who had BRCA mutations.
This slide shows you the results from that study.
We found that women with BRCA mutations had
much fewer oocytes and much lower numbers of embryos.
1:33
Our studies also showed that women with BRCA1 mutations have lower ovarian reserve.
Serum AMH is the most sensitive marker of ovarian reserve.
In a study in 2013, a prospective study, we found that women,
especially with BRCA1 mutations, had lower serum AMH levels compared to those who were negative.
These findings were since confirmed by multiple studies,
as you see on this slide, around seven studies.
Hide